1314PAssociation between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK

J. von Pawel; K. Syrigos; J. Mazieres; D. Cortinovis; R. Dziadziuszko; D.R. Gandara; P. Conkling; J. Goldschmidt; C.A. Thomas; R. Bordoni; M. Kosty; F.S. Braiteh; S. Hu; M. Ballinger; H. Patel; M. Gandhi; L. Fehrenbacher

doi:10.1093/ANNONC/MDX380.017

1314PAssociation between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK

J. von Pawel
, K. Syrigos
, J. Mazieres
, D. Cortinovis
, R. Dziadziuszko
, D.R. Gandara
, P. Conkling
, J. Goldschmidt
, C.A. Thomas
, R. Bordoni
, M. Kosty
, F.S. Braiteh
, S. Hu
, M. Ballinger
, H. Patel
, M. Gandhi
, L. Fehrenbacher

Medical Oncoloy, Asklepios-Fachklinikum, Gauting, Germany
3rd Department of Medicine, Athens School of Medicine, Athens, Greece
University of Toulouse
Medical Oncology Unit, AOU San Gerardo, Monza, Italy
Gdańsk Medical University
University of California, Davis
Medical Oncoloy, Virginia Oncology Associates, Norfolk, VA, USA
Clinical Research, Blue Ridge Cancer Care, Blacksburg, USA
Medical Oncoloy, New England Cancer Specialists, Scarborough, ME, USA
Northside Hospital
Scripps Health
Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, USA
Genentech
Kaiser Permanente

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Annals of Oncology
Volume	28
DOIs	https://doi.org/10.1093/ANNONC/MDX380.017
State	Published - Sep 1 2017
Externally published	Yes

Disciplines

Medicine and Health Sciences
Critical Care

Access to Document

10.1093/ANNONC/MDX380.017License: Unspecified

Cite this

von Pawel, J., Syrigos, K., Mazieres, J., Cortinovis, D., Dziadziuszko, R., Gandara, D. R., Conkling, P., Goldschmidt, J., Thomas, C. A., Bordoni, R., Kosty, M., Braiteh, F. S., Hu, S., Ballinger, M., Patel, H., Gandhi, M., & Fehrenbacher, L. (2017). 1314PAssociation between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK. Annals of Oncology, 28. https://doi.org/10.1093/ANNONC/MDX380.017

von Pawel, J, Syrigos, K, Mazieres, J, Cortinovis, D, Dziadziuszko, R, Gandara, DR, Conkling, P, Goldschmidt, J, Thomas, CA, Bordoni, R, Kosty, M, Braiteh, FS, Hu, S, Ballinger, M, Patel, H, Gandhi, M & Fehrenbacher, L 2017, '1314PAssociation between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK', Annals of Oncology, vol. 28. https://doi.org/10.1093/ANNONC/MDX380.017

@article{3d429f95bb744d76a2860b014573d681,

title = "1314PAssociation between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK",

author = "\{von Pawel\}, J. and K. Syrigos and J. Mazieres and D. Cortinovis and R. Dziadziuszko and D.R. Gandara and P. Conkling and J. Goldschmidt and C.A. Thomas and R. Bordoni and M. Kosty and F.S. Braiteh and S. Hu and M. Ballinger and H. Patel and M. Gandhi and L. Fehrenbacher",

note = "Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines † Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group Visibility.",

year = "2017",

month = sep,

day = "1",

doi = "10.1093/ANNONC/MDX380.017",

language = "American English",

volume = "28",

journal = "Annals of Oncology",

issn = "1569-8041",

publisher = "Elsevier",

}

TY - JOUR

T1 - 1314PAssociation between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK

AU - von Pawel, J.

AU - Syrigos, K.

AU - Mazieres, J.

AU - Cortinovis, D.

AU - Dziadziuszko, R.

AU - Gandara, D.R.

AU - Conkling, P.

AU - Goldschmidt, J.

AU - Thomas, C.A.

AU - Bordoni, R.

AU - Kosty, M.

AU - Braiteh, F.S.

AU - Hu, S.

AU - Ballinger, M.

AU - Patel, H.

AU - Gandhi, M.

AU - Fehrenbacher, L.

N1 - Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines † Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group Visibility.

PY - 2017/9/1

Y1 - 2017/9/1

UR - https://academic.oup.com/annonc/article/28/suppl_5/mdx380.017/4109372

U2 - 10.1093/ANNONC/MDX380.017

DO - 10.1093/ANNONC/MDX380.017

M3 - Article

SN - 1569-8041

VL - 28

JO - Annals of Oncology

JF - Annals of Oncology

ER -

1314PAssociation between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK

Disciplines

Access to Document

Other files and links

Cite this